Clinical Trial Update: Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma [Phase 3]

View source ↗

Summary

A Phase 3 trial is planned to compare lorlatinib with concurrent or sequential chemoradiotherapy in stage III ALK-positive non-small cell lung cancer; the study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• lorlatinib (lorlatinib)

Snippet

Sponsor: Guangdong Association of Clinical Trials | Conditions: Neoadjuvant Non-Small Cell Lung Cancer | Phase 3 | Status: NOT_YET_RECRUITING